Novel indications for BRCA1 screening using individual clinical and morphological features

International Journal of Cancer

Volumn 84, Issue 3, 1999, Pages 263-267

  Eisinger, François ^a   Noguès, Catherine ^b   Guinebretière, Jean Marc ^c   Peyrat, Jean Philippe ^d   Bardou, Valérie Jeanne ^a   Noguchi, Tetsuro ^a   Vennin, Philippe ^e   Sauvan, Richard ^a   Lidereau, Rosette ^b   Birnbaum, Daniel ^a   Jacquemier, Jocelyne ^a   Sobol, Hagay ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b Rene Huguenin Centre   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Center Oscar Lambret   (France)

^e Oscar Lambret Institute   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER SCREENING; CANCER SUSCEPTIBILITY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION;

EID: 0033029560     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990621)84:3<263::AID-IJC11>3.0.CO;2-G     Document Type: Article

References (29)

1. ABELOVICH, D., KADURI, L., LERER, I., WEINBERG, N., AMIR, G., SAGI, M., ZLOTOGORA, J., HECHING, N. and PERETZ, T., The founder mutations 185delAG and 5383insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian-cancer and in 30% of early-onset breast-cancer patients among Ashkenazi women. Amer. J. hum. Genet., 60, 505-514 (1997).
2. ASCO, Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J. clin. Oncol., 14, 1730-1736 (1996).
3. BOUVIER-COLLE, M.H., Des femmes dans la société française: liberté, égalité, différences. In: M.J. Saurel-Cubizolles and B. Blondel (eds.), La santé des femmes, pp. 3-13, Médecine-Sciences/Flammarion, Paris (1996).
4. BURKE, W. and 12 OTHERS, Recommendations for follow-up care of individuals with inherited predisposition to cancer, II. BRCA1 and BRCA2. J. Amer. med. Ass., 277, 997-1003 (1997).
5. CONTESSO, G., MOURIESSE, H., FRIEDMAN, S., GENIN, J., SARRAZIN, D. and ROUESSE, J., The importance of histologic grade in long-term prognosis of breast cancer: a study of 1010 patients, uniformly treated at the Institut Gustave Roussy. J. clin. Oncol., 5, 1378-1386 (1987).
6. COUCH, F., DE SHANO, M., BLACKWOOD, M., CALZONE, K., STOPFER, J., CAMPEAU, L., GANGULY, A., REBBECK, T. and WEBER, B., BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. New Engl. J. Med., 336, 1409-1415 (1997).
7. EASTON, D.F., FORD, D., BISHOP, D.T. and THE BREAST-CANCER LINKAGE CONSORTIUM, Breast- and ovarian-cancer incidence in BRCA1-mutation carriers. Amer. J. hum. Genet., 56, 265-271 (1995).
8. EISINGER, F. and 14 OTHERS, Recommendations for medical management of hereditary breast ovarian cancer: the French national Ad Hoc committee. Ann. Oncol., 9, 939-950 (1998a).
9. EISINGER, F., JACQUEMIER, J., CHARPIN, C., STOPPA-LYONNET, D., BRESSAC-DE PAILLERETS, B., PEYRAT, J.-P., LONGY, M., GUINEBRETIÈRE, J.-M., SAUVAN, R., NOGUCHI, T., BIRNBAUM, D. and SOBOL, H., Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res., 58, 1588-1592 (1998a).
10. EISINGER, F., JACQUEMIER, J., GUINEBRETIÈRE, J.-M., BIRNBAUM, D. and SOBOL, H., p53 involvement in BRCA1-associated breast cancer. Lancet, 350, 1101 (1997).
11. EISINGER, F., NOGUÈS, C., BIRNBAUM, D., JACQUEMIER, J. and SOBOL, H., BRCA1 and medullary breast cancer. J. Amer. med. Ass., 280, 1227-1228 (1998c).
12. EISINGER, F., SOBOL, H., SERIN, D. and WHORTON, J., Hereditary breast cancer, circa 1750. Lancet, 351, 1366 (1998d).
13. EISINGER, F., STOPPA-LYONNET, D., LONGY, M., KERANGUEVEN, F., NOGUCHI, T., BAILLY, C., VINCENT-SALOMON, A., JACQUEMIER, J., BIRNBAUM, D. and SOBOL, H., Germ-line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res., 56, 471-474 (1996).
14. FITZGERALD, M. and 18 OTHERS, Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. New Engl. J. Med., 334, 143-149 (1996).
15. FORD, D. and 38 OTHERS. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast-cancer families. Amer. J. Hum. Genet., 62, 679-689 (1998).
16. HAUT COMITÉ DE SANTÉ PUBLIQUE, La santé en France, Annexes: travaux des groupes thématiques. La Documentation Française, Paris (1994).
17. HULKA, B.S. and MARGOLIN, B.H., Methodological issues in epidemiologic studies using biologic markers. Amer. J. Epidemiol., 135, 200-209 (1992).
18. JOHANNSSON, O., IDVALL, I., ANDERSON, C., BORG, A., BARKARDOTTIR, R., EGILSON, V. and OLSSON, H., Tumor biological features of BRCA1-induced breast and ovarian cancer. Europ, J. Cancer, 33, 362-371 (1997).
19. LAKHANI, S. and 40 OTHERS, Pathology of familial breast cancer (II): multifactorial analysis of morphological differences between breast cancers due to BRCA1, BRCA2 and controls. J. nat. Cancer Inst., 90, 1138-1145 (1998).
20. MALONE, K., DALING, J., THOMPSON, J., O'BRIEN, C., FRANCISCO, L. and OSTRANDER, E., BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. J. Amer. med. Ass., 279, 922-929 (1998).
21. MARCUS, J., WATSON, P., PAGE, D., NAROD, S., LENOIR, S., TONIN, P., LINDER-STEPHENSON, L., CONWAY, T. and LYNCH, H., Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer, 77, 697-709 (1996).
22. NEWMAN, B., MU, H., BUTLER, L., MILLIKAN, R., MOORMAN, P. and KING, M.-C., Frequency of breast cancer attribuable to BRCA1 in a population-based series of American women. J. Amer. med. Ass., 279, 915-921 (1998).
23. NOVAKOVIC, B., GOLSTEIN, A. and TUCKER, M., Validation of familial history of cancer in deceased family members. J. nat. Cancer Inst., 88, 1492-1493 (1996).
24. REINER, A., REINER, G., SPONA, J., SCHEMPER, M. and HOLZNER, J., Histopathologic characterization of human breast cancer in correlation with estrogen-receptor status. Cancer, 61, 1149-1154 (1988).
25. SHATTUCK-EIDENS, D. and 58 OTHERS, BRCA1-sequence analysis in women at high risk for susceptibility mutations: risk-factor analysis and implications for genetic testing. J. Amer. med. Ass., 278, 1242-1250 (1997).
26. SOBOL, H., BIGNON, Y., CUISENIER, J., STOPPA-LYONNET, D., NOGUÈS, C. EISINGER, F. and LE GROUPE GÉNÉTIQUE ET CANCER DE LA FNCLCC, Les consultations d'oncogénétique en 1994, analyse de l'activité: enquête sur 203 consultations. In: M. Boiron and M. Marty (eds.), Eurocancer95, pp. 43-46, John Libbey Eurotext, Paris (1995).
27. SOBOL, H., STOPPA-LYONNET, D., BRESSAC-DE-PAILLERETS, B., PEYRAT, J.P., KERANGUEVEN, F., JANIN, N., NOGUCHI, T., EISINGER, F., GUINEBRETIÈRE, J.M., JACQUEMIER, J. and BIRNBAUM, D., Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers. Cancer Res., 56, 3216-3219 (1996).
28. STRUEWING, J., HARTGE, P., WACHOLDER, S., BAKER, S., BERLIN, M., MCADAMS, M., TIMMERMAN, M., BRODY, L. and UCKER, M., The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New Engl. J. Med., 336, 1401-1408 (1997).
29. WHITTEMORE, A., GONG, G. and ITNYRE, J., Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Amer. J. hum. Genet., 60, 496-504 (1997).